How a Nutraceutical Company Leveraged C. elegans to Predict the Most Valuable Compound to Develop
Traditionally, clients of NemaMetrix’s in-vivo testing services are pharmaceutical companies investigating chemically synthesized small molecules for efficacy on a specific gene target of interest. However we have been seeing an increase in Nutraceutical clients wishing to investigate the impact of naturally derived compounds or mixtures.
Dr. Johnson is the CSO of a small nutraceutical company based in Germany and is developing compounds that promote healthy aging.
Dr. Johnson needed to apply for patents and start to commercialize the compounds within the next 6-10 months. To do so, she needed in-vivo analysis of her compounds in an intact animal, but using rodents as a model would be much too long and too costly at this stage. She needed fast data that is still relevant for human health.
We used the animal model C. elegans to perform a set of specific experiments designed by our experts to provide rapid and reliable data based on Dr. Johnson’s priorities.
NemaMetrix is the market leader for early preclinical in-vivo testing using small animal models to gain a better understanding of the efficacy, mode of action, toxicity and potential targets for novel compounds. Using the data that we provided, Dr. Johnson was able to apply for multiple patents in a timely manner.